Risks
4 risks
Risk Intelligence
US price erosion continues at mid-single digit
View Risks →Alkem Laboratories Limited — Q3 FY25
Alkem reported Q3 FY25 revenue of INR 3,374 crore (+1.5% YoY) and EBITDA margin of 22.5% (+7.3% YoY), driven by cost optimization and focus on higher-margin offerings.
bullish
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem reported Q3 FY25 revenue of INR 3,374 crore (+1.5% YoY) and EBITDA margin of 22.5% (+7.3% YoY), driven by cost optimization and focus on higher-margin offerings. Domestic branded generic growth of 6% was in line with the market, with 32 of top 50 brands gaining share. The US business improved to -7% YoY (vs -22% in Q2) as supply normalized. Management maintained full-year EBITDA margin guidance of 19%, citing higher R&D spend in Q4 for five ANDA filings. Key growth drivers include GLP-1 (semaglutide) launch readiness, two acquisitions (Adroid and Bombay Ortho) in dermato-cosmetology and ortho implants, and a net cash position of INR 4,700 crore for potential M&A. Risk: sustained price erosion in US generics and acute therapy slowdown in India could pressure top-line growth.
अल्केम ने तीसरी तिमाही में 3,374 करोड़ रुपये की कमाई की, जो पिछले साल से 1.5% ज्यादा है। कंपनी का मुनाफा (EBITDA मार्जिन) 22.5% रहा, जो पिछले साल से 7.3% बढ़ा। यह खर्च कम करने और ज्यादा मुनाफे वाले उत्पादों पर ध्यान देने से हुआ। भारत में कंपनी के ब्रांडेड जेनेरिक दवाओं की बिक्री 6% बढ़ी, और 50 में से 32 ब्रांडों की बाजार हिस्सेदारी बढ़ी। अमेरिका में कारोबार में सुधार हुआ, अब पिछले साल से सिर्फ 7% कम है (पिछली तिमाही में 22% कम था)। कंपनी ने पूरे साल 19% मुनाफा रहने का अनुमान लगाया है। नई दवाओं (ANDA) के लिए चौथी तिमाही में ज्यादा खर्च होगा। कंपनी के पास 4,700 करोड़ रुपये नकद हैं, जिससे वह नई कंपनियां खरीद सकती है। जोखिम: अमेरिका में दवाओं की कीमतें गिर सकती हैं और भारत में कुछ दवाओं की मांग कम हो सकती है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Domestic volume growth
1.1%
+0.8pp YoY
India pharma market volume growth was only 0.3% in Q3; Alkem outperformed.
Pan-D market share
40.4%
+1.9pp YoY
Highest ever market share for Alkem's top brand, with 15.5% value growth.
US back orders
2%
-36pp YoY
Improved from 38% last year; supply normalization driving US recovery.
Net cash position
INR 4,700 crore
N/A
Zero leverage; war chest for acquisitions in branded Rx and MedTech.
What Changed vs Last Quarter
NEW
Full-year EBITDA margin guidance maintained at 19%
Despite 21.6% margin in 9M, Q4 is seasonally weak with higher R&D spend (5 filings), so full-year margin expected around 19%.
NEW
Domestic business to grow in line with IPM (~7%) for FY25
Q4 implied growth of ~9.5-10% driven by strong secondary optics and low base.
NEW
US business expected to be flat YoY in Q4
Improved from -22% in Q2 to -7% in Q3; supply normalization should lead to neutral growth by Q4.
NEW
Semaglutide launch in first wave in India
Alkem has developed its own product, filed with regulator, and plans to be among the first to launch.
DROPPED
Domestic revenue growth of 8-9% for FY25
Management maintains full-year domestic growth guidance of 8-9%, with Q4 expected to be particularly strong.
DROPPED
EBITDA margin improvement of ~100bps to 18.5-19% for FY25
Full-year EBITDA margin expected to be 18.5-19%, driven by cost controls and product mix improvement.
DROPPED
US business flattish to mid-single-digit erosion for FY25
US revenue expected to decline flattish to mid-single-digit for the full year, with H2 performance better than H1.
DROPPED
Enzyme plant commissioning by Q4 FY25 or Q1 FY26
The US biologic CDMO plant is expected to begin production by Q4 FY25 or Q1 FY26, with break-even targeted in the first year.
NEW RISK
US price erosion continues at mid-single digit
Price erosion in US generics is ~5% (2.5% on NRV basis) and expected to persist, pressuring US revenue growth.
NEW RISK
Acute therapy slowdown in India
India acute market growth slowed to 5.7% in Q3; Alkem's trade generics business (20% of domestic) was flat due to competition and pricing pressure.
NEW RISK
Chile currency and tender loss impact
Chile business declined ~30% due to exiting a low-priced tender and Chilean peso depreciation; recovery uncertain.
NEW RISK
Pen G price increase may pressure margins
Pen G prices rose 20-25% in last two months; if sustained, could impact input costs for Alkem's penicillin-based products.
RISK GONE
Acute market weakness persists
The acute therapy market, especially anti-infectives, continues to show sluggish growth, impacting Alkem's high-acute portfolio.
RISK GONE
US pricing pressure and supply chain recovery
US business faces ongoing price erosion (6% in Q2) and the need to regain lost contracts after past supply issues.
RISK GONE
Exactech bankruptcy proceedings may affect MedTech launch
Partner Exactech is undergoing bankruptcy, which could disrupt technology transfer and launch timelines for the MedTech business.
RISK GONE
Market share loss in key anti-infective brands
Brands like Clavam and Xone have lost market share, partly due to increased competition from smaller players post-COVID.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q4 FY24
Q4 had INR 30 crore in service-level penalties due to supply issues; if not resolved, could impact US margins.
Mentioned in Q2 FY25, Q4 FY24
Management maintains full-year domestic growth guidance of 8-9%, with Q4 expected to be particularly strong.
Mentioned in Q2 FY25, Q3 FY24
Full-year EBITDA margin expected to be 18.5-19%, driven by cost controls and product mix improvement.
Mentioned in Q1 FY25, Q2 FY24
Q2 and Q3 typically see higher anti-infective sales, which could lower margins by ~2% due to product mix shift.
Fast read
Guidance and risk preview
Despite 21.6% margin in 9M, Q4 is seasonally weak with higher R&D spend (5 filings), so full-year margin expected around 19%.
Price erosion in US generics is ~5% (2.5% on NRV basis) and expected to persist, pressuring US revenue growth.
View Risks →